Long-term Safety of Crisaborole, a Novel, Nonsteroidal, Topical, Anti-inflammatory, Phosphodiesterase 4 Inhibitor in Children and Adults with Mild to Moderate Atopic Dermatitis

Mapping Intimacies ◽

10.1542/peds.141.1_meetingabstract.271 ◽

2018 ◽

Author(s):

Lawrence F. Eichenfield ◽

Robert S. Call ◽

Douglass W. Forsha ◽

Joseph Fowler ◽

Adelaide A. Hebert ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phosphodiesterase 4 ◽

Anti Inflammatory ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

A Novel Nonsteroidal, Topical Anti-inflammatory, Phosphodiesterase 4 Inhibitor, Crisaborole Ointment, Reduced Pruritus and Signs of Atopic Dermatitis in 2 Phase 3 Studies in Children and Adults

10.1542/peds.141.1_meetingabstract.251 ◽

2018 ◽

Author(s):

Adelaide A. Hebert ◽

Lawrence F. Eichenfield ◽

Mark G. Lebwohl ◽

Amy S. Paller ◽

Eric L. Simpson ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Anti Inflammatory ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

Phase 3 Studies Treating Children and Adult Patients with Mild to Moderate Atopic Dermatitis with Crisaborole Ointment, a Novel, Nonsteroidal, Topical Anti-inflammatory, Phosphodiesterase 4 Inhibitor

10.1542/peds.141.1_meetingabstract.275 ◽

2018 ◽

Author(s):

Amy S. Paller ◽

Wynnis L. Tom ◽

Mark G. Lebwohl ◽

Mark Boguniewicz ◽

Lawrence F. Eichenfield ◽

...

Keyword(s):

Atopic Dermatitis ◽

Adult Patients ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Anti Inflammatory ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

Clinical anti-inflammatory efficacy of arofylline, a new selective phosphodiesterase-4 inhibitor, in dogs with atopic dermatitis

Veterinary Record ◽

10.1136/vr.145.7.191 ◽

1999 ◽

Vol 145 (7) ◽

pp. 191-194 ◽

Cited By ~ 25

Author(s):

L. Ferrer ◽

J. Alberola ◽

M. Queralt ◽

P. Brazis ◽

R. Rabanal ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phosphodiesterase 4 ◽

Anti Inflammatory ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

TAS-203, an oral phosphodiesterase 4 inhibitor, exerts anti-inflammatory activities in a rat airway inflammation model

European Journal of Pharmacology ◽

10.1016/j.ejphar.2019.01.068 ◽

2019 ◽

Vol 849 ◽

pp. 22-29 ◽

Cited By ~ 2

Author(s):

Shunsuke Demizu ◽

Naomasa Asaka ◽

Hiroyuki Kawahara ◽

Eiji Sasaki

Keyword(s):

Airway Inflammation ◽

Phosphodiesterase 4 ◽

Inflammation Model ◽

Anti Inflammatory ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

CHF6001 I: A Novel Highly Potent and Selective Phosphodiesterase 4 Inhibitor with Robust Anti-Inflammatory Activity and Suitable for Topical Pulmonary Administration

Journal of Pharmacology and Experimental Therapeutics ◽

10.1124/jpet.114.220541 ◽

2015 ◽

Vol 352 (3) ◽

pp. 559-567 ◽

Cited By ~ 40

Author(s):

Nadia Moretto ◽

Paola Caruso ◽

Raffaella Bosco ◽

Gessica Marchini ◽

Fiorella Pastore ◽

...

Keyword(s):

Inflammatory Activity ◽

Pulmonary Administration ◽

Phosphodiesterase 4 ◽

Anti Inflammatory ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

SAT0568 Long-Term Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Analysis of 3 Phase 3 Studies

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.3590 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 866.2-866 ◽

Cited By ~ 2

Author(s):

F. Zhang ◽

Z. Clancy ◽

S. Li

Keyword(s):

Psoriatic Arthritis ◽

Work Productivity ◽

Pooled Analysis ◽

Phase 3 ◽

Productivity Improvement ◽

Phosphodiesterase 4 ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

165 Apremilast, an oral phosphodiesterase-4 inhibitor, is associated with long-term (156-week) improvements in Bath Ankylosing Spondylitis Disease Activity Index Score in subjects with psoriatic arthritis: pooled results from three phase III randomised controlled trials

Rheumatology ◽

10.1093/rheumatology/key075.389 ◽

2018 ◽

Vol 57 (suppl_3) ◽

Author(s):

Philip J Mease ◽

Helena Marzo-Ortega ◽

Airi Poder ◽

Filip Van den Bosch ◽

Jurgen Wollenhaupt ◽

...

Keyword(s):

Randomised Controlled Trials ◽

Activity Index ◽

Disease Activity Index ◽

Phase Iii ◽

Phosphodiesterase 4 ◽

Three Phase ◽

Activity Index Score ◽

Randomised Controlled ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

FRI0470 Long-Term (156-Week) Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2016-eular.3265 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 608.1-608

Author(s):

P.J. Mease ◽

D.D. Gladman ◽

J.J. Gomez-Reino ◽

S. Hall ◽

A. Kavanaugh ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Randomized Controlled Trials ◽

Safety Profile ◽

Safety Analysis ◽

Phase Iii ◽

Controlled Trials ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

LB0001 Long-Term (52-Week) Results of a Phase 3, Randomized, Controlled Trial of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-eular.526 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A163-A163 ◽

Cited By ~ 5

Author(s):

A. Kavanaugh ◽

P. J. Mease ◽

A. O. Adebajo ◽

J. Wollenhaupt ◽

C. Hu ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Psoriatic Arthritis ◽

Controlled Trial ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

SAT-356-Anti-metabolic, anti-inflammatory and anti-fibrotic properties of ART-, a novel phosphodiesterase 4 inhibitor as a potential clinical candidate for non-alcoholic steatohepatitis

Journal of Hepatology ◽

10.1016/s0618-8278(19)31586-5 ◽

2019 ◽

Vol 70 (1) ◽

pp. e796

Author(s):

Yuichiro Amano ◽

Shuntarou Tsuchiya ◽

Mitsuharu Matsumoto ◽

Hikaru Ueno ◽

Nobuhiro Nishigaki ◽

...

Keyword(s):

Phosphodiesterase 4 ◽

Alcoholic Steatohepatitis ◽

Anti Inflammatory ◽

Phosphodiesterase 4 Inhibitor ◽

Clinical Candidate

Download Full-text